Menu Search
Equities

Bioporto A/S

BIOPOR:CPH

Bioporto A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)1.91
  • Today's Change-0.014 / -0.73%
  • Shares traded110.22k
  • 1 Year change+13.05%
  • Beta1.3920
Data delayed at least 15 minutes, as of Sep 20 2024 11:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in DKK

The one analyst offering a 12 month price target expects BioPorto A/S share price to rise to 3.00 in the next year from the last price of 1.92.
High56.3%3.00
Med56.3%3.00
Low56.3%3.00

Earnings history & estimates in DKK

On Aug 15, 2024, BioPorto A/S reported 2nd quarter 2024 losses of -0.04 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 33.33%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate-1.29%
BioPorto A/S reported annual 2023 losses of -0.16 per share on Feb 22, 2024.
Average growth rate+14.46%
More ▼

Revenue history & estimates in DKK

BioPorto A/S had 2nd quarter 2024 revenues of 9.20m. This bettered the 8.40m estimate of the one analyst covering the company. This was 14.41% above the prior year's 2nd quarter results.
Average growth rate+7.19%
BioPorto A/S had revenues for the full year 2023 of 30.96m. This was 6.87% above the prior year's results.
Average growth rate+4.50%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.